GW Still Sees Future For Sativex In US
MS Spasticity Drug Struggling in Europe
The UK firm is starting an additional Phase III trial of 450 patients to supplement positive data from the three European Phase III trials it has already concluded in a bid to convince the FDA of Sativex's potential.
